Cargando…
Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing
OBJECTIVES: Tumor biomarker analyses accompanying immuno-oncology therapies are coupled with a tumor tissue journey aiming to guide tissue procurement and allow for accurate diagnosis and delivery of test results. The engagement of pathologists in the tumor tissue journey is essential because they a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130880/ https://www.ncbi.nlm.nih.gov/pubmed/33582767 http://dx.doi.org/10.1093/ajcp/aqaa212 |
_version_ | 1783694603667374080 |
---|---|
author | De Las Casas, Luis E Hicks, David G |
author_facet | De Las Casas, Luis E Hicks, David G |
author_sort | De Las Casas, Luis E |
collection | PubMed |
description | OBJECTIVES: Tumor biomarker analyses accompanying immuno-oncology therapies are coupled with a tumor tissue journey aiming to guide tissue procurement and allow for accurate diagnosis and delivery of test results. The engagement of pathologists in the tumor tissue journey is essential because they are able to link the preanalytic requirements of this process with pathologic evaluation and clinical information, ultimately influencing treatment decisions for patients with cancer. The aim of this review is to provide suggestions on how cancer diagnosis and the delivery of molecular test results may be optimized, based on the needs and available resources of institutions, by placing the tumor tissue journey under the leadership of pathologists. METHODS: Literature searches on PubMed and personal experience provided the necessary material to satisfy the objectives of this review. RESULTS: Pathologists are usually involved across many steps of the tumor tissue journey and have the requisite knowledge to ensure its efficiency. CONCLUSIONS: The expansion of oncology diagnostic testing emphasizes the need for pathologists to acquire a leadership role in the multidisciplinary effort to optimize the accuracy, completeness, and delivery of diagnoses guiding personalized treatments. |
format | Online Article Text |
id | pubmed-8130880 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-81308802021-05-21 Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing De Las Casas, Luis E Hicks, David G Am J Clin Pathol Review Articles OBJECTIVES: Tumor biomarker analyses accompanying immuno-oncology therapies are coupled with a tumor tissue journey aiming to guide tissue procurement and allow for accurate diagnosis and delivery of test results. The engagement of pathologists in the tumor tissue journey is essential because they are able to link the preanalytic requirements of this process with pathologic evaluation and clinical information, ultimately influencing treatment decisions for patients with cancer. The aim of this review is to provide suggestions on how cancer diagnosis and the delivery of molecular test results may be optimized, based on the needs and available resources of institutions, by placing the tumor tissue journey under the leadership of pathologists. METHODS: Literature searches on PubMed and personal experience provided the necessary material to satisfy the objectives of this review. RESULTS: Pathologists are usually involved across many steps of the tumor tissue journey and have the requisite knowledge to ensure its efficiency. CONCLUSIONS: The expansion of oncology diagnostic testing emphasizes the need for pathologists to acquire a leadership role in the multidisciplinary effort to optimize the accuracy, completeness, and delivery of diagnoses guiding personalized treatments. Oxford University Press 2021-02-14 /pmc/articles/PMC8130880/ /pubmed/33582767 http://dx.doi.org/10.1093/ajcp/aqaa212 Text en © American Society for Clinical Pathology, 2021. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Articles De Las Casas, Luis E Hicks, David G Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing |
title | Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing |
title_full | Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing |
title_fullStr | Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing |
title_full_unstemmed | Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing |
title_short | Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing |
title_sort | pathologists at the leading edge of optimizing the tumor tissue journey for diagnostic accuracy and molecular testing |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130880/ https://www.ncbi.nlm.nih.gov/pubmed/33582767 http://dx.doi.org/10.1093/ajcp/aqaa212 |
work_keys_str_mv | AT delascasasluise pathologistsattheleadingedgeofoptimizingthetumortissuejourneyfordiagnosticaccuracyandmoleculartesting AT hicksdavidg pathologistsattheleadingedgeofoptimizingthetumortissuejourneyfordiagnosticaccuracyandmoleculartesting |